| Year |
Citation |
Score |
| 2022 |
Iversen ES, Lipton G, Hart SN, Lee KY, Hu C, Polley EC, Pesaran T, Yussuf A, LaDuca H, Chao E, Karam R, Goldgar DE, Couch FJ, Monteiro ANA. An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance. Npj Genomic Medicine. 7: 35. PMID 35665744 DOI: 10.1038/s41525-022-00302-3 |
0.322 |
|
| 2020 |
Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS. Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing. Human Mutation. PMID 32442341 DOI: 10.1002/Humu.24053 |
0.371 |
|
| 2020 |
Palmer JR, Polley EC, Hu C, John EM, Haiman C, Hart SN, Gaudet M, Pal T, Anton-Culver H, Trentham-Dietz A, Bernstein L, Ambrosone CB, Bandera EV, Bertrand KA, Bethea TN, et al. Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. Journal of the National Cancer Institute. PMID 32427313 DOI: 10.1093/Jnci/Djaa040 |
0.393 |
|
| 2020 |
Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902190. PMID 32125938 DOI: 10.1200/Jco.19.02190 |
0.35 |
|
| 2020 |
Golmakani MK, Polley EC. Super Learner for Survival Data Prediction. The International Journal of Biostatistics. PMID 32097120 DOI: 10.1515/Ijb-2019-0065 |
0.326 |
|
| 2020 |
Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. Journal of the National Cancer Institute. PMID 32091585 DOI: 10.1093/Jnci/Djaa023 |
0.399 |
|
| 2020 |
Gao C, Polley EC, Hu C, Hart SN, Gnanaolivu R, Lee KY, Na J, Boddicker NJ, Samara R, Auer P, Bernstein L, Gaudet M, Trentham-Dietz A, Yao S, Haiman C, et al. Abstract PD3-02: Polygenic risk scores provide clinically meaningful risk stratification among women carrying moderate penetrance pathogenic variants in breast cancer predisposition genes: Results from the CARRIERS study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd3-02 |
0.401 |
|
| 2020 |
Couch FJ, Hu C, Hart SN, Gnanaolivu R, Lee KY, Na J, Gao C, Boddicker NJ, Eckloff B, Samara R, Klebba J, Ambrosone CB, Anton-Culver H, Auer P, Bernstein L, ... ... Polley EC, et al. Abstract PD3-01: Population-based breast cancer risk estimates for predisposition gene mutations: Results from the CARRIERS study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd3-01 |
0.419 |
|
| 2020 |
Yadav S, LaDuca H, Polley EC, Hu C, Hart SN, Na J, Gnanaolivu R, Smith B, Goldgar DE, Pesaran T, Dolinsky JS, Couch FJ. Abstract P6-08-04: Germline mutations in cancer predisposition genes in patients with invasive lobular carcinoma of the breast Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-08-04 |
0.366 |
|
| 2020 |
Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Olson JE, Ruddy KJ, Couch FJ. Abstract P6-08-01: Comparison of recommendations for germline genetic testing in an unselected cohort of patients with breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-08-01 |
0.367 |
|
| 2020 |
Black MH, Li S, LaDuca H, Armasu S, Polley EC, Fitz-Gibbon P, Scott CG, Winham SJ, Olson JE, Ruddy KJ, Vachon CM, Couch FJ. Abstract P5-07-06: Performance of a polygenic risk score combined with clinical assessment for breast cancer risk Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-07-06 |
0.4 |
|
| 2020 |
Giridhar KV, Choong GM, Yadav S, Polley EC, Leon-Ferre RA, Liu MC, Goetz MP, Couch FJ. Abstract P5-03-07: Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-03-07 |
0.367 |
|
| 2019 |
Li H, LaDuca H, Pesaran T, Chao EC, Dolinsky JS, Parsons M, Spurdle AB, Polley EC, Shimelis H, Hart SN, Hu C, Couch FJ, Goldgar DE. Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31853058 DOI: 10.1038/S41436-019-0729-1 |
0.371 |
|
| 2019 |
Choudhery S, Polley E, Conners AL. Assessment of MRI-detected lesions on screening tomosynthesis in patients with newly diagnosed breast cancer. Clinical Imaging. 59: 50-55. PMID 31760277 DOI: 10.1016/J.Clinimag.2019.09.007 |
0.312 |
|
| 2019 |
LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, Yadav S, Hu C, Na J, Goldgar DE, Fulk K, Smith LP, Horton C, Profato J, Pesaran T, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31406321 DOI: 10.1038/S41436-019-0633-8 |
0.398 |
|
| 2019 |
Vachon CM, Scott CG, Tamimi RM, Thompson DJ, Fasching PA, Stone J, Southey MC, Winham S, Lindström S, Lilyquist J, Giles GG, Milne RL, MacInnis RJ, Baglietto L, Li J, ... ... Polley EC, et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research : Bcr. 21: 68. PMID 31118087 DOI: 10.1186/S13058-019-1138-8 |
0.328 |
|
| 2019 |
Liu Y, Chanana P, Davila JI, Hou X, Zanfagnin V, McGehee CD, Goode EL, Polley EC, Haluska P, Weroha SJ, Wang C. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Scientific Reports. 9: 6314. PMID 31004097 DOI: 10.1038/S41598-019-42680-2 |
0.307 |
|
| 2019 |
Yang SX, Polley EC. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. Breast Cancer Research and Treatment. PMID 30746635 DOI: 10.1007/S10549-019-05142-X |
0.349 |
|
| 2019 |
Long B, Lilyquist J, Weaver A, Hu C, Gnanaolivu R, Lee KY, Hart SN, Polley EC, Bakkum-Gamez JN, Couch FJ, Dowdy SC. Cancer susceptibility gene mutations in type I and II endometrial cancer. Gynecologic Oncology. 152: 20-25. PMID 30612635 DOI: 10.1016/J.Ygyno.2018.10.019 |
0.39 |
|
| 2019 |
Yadav S, LaDuca H, Polley E, Shimelis H, Niguidula N, Hu C, Lilyquist J, Na J, Lee K, Gutierrez S, Yussuf A, Hart S, Davis BT, Chao E, Pesaran T, et al. Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer patients. Journal of Clinical Oncology. 37: 1514-1514. DOI: 10.1200/Jco.2019.37.15_Suppl.1514 |
0.402 |
|
| 2019 |
Palmer JR, Hu C, Hart S, Gnanaolivu RD, Gao C, Anton-Culver H, Trentham-Dietz A, Bernstein L, Weitzel JN, Domchek SM, Goldgar D, Nathanson K, Pal T, John EM, Gaudet M, ... ... Polley E, et al. Genetic predisposition to breast cancer among African American women. Journal of Clinical Oncology. 37: 104-104. DOI: 10.1200/Jco.2019.37.15_Suppl.104 |
0.412 |
|
| 2019 |
Couch F, Hu C, Hart S, Gnanaolivu R, Lilyquist J, Lee K, Gao C, Eckloff B, Samara R, Klebba J, Auer P, Bernstein L, Gaudet M, Haiman C, Palmer J, ... ... Polley E, et al. Abstract GS2-01: Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs2-01 |
0.422 |
|
| 2019 |
Gao C, Hu C, Hart SN, Gnanaolivu R, Lee KY, Lilyquist J, Boddicker NJ, Eckloff B, Samara R, Klebba J, Auer P, Bernstein L, Gaudet M, Anton-Culver H, Trentham-Dietz A, ... ... Polley EC, et al. Abstract 4177: The joint effects of polygenic risk scores and pathogenic variants in cancer predisposition genes on breast cancer risk in the general population: results from the CARRIERS study Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4177 |
0.383 |
|
| 2019 |
Couch FJ, Hu C, Hart SN, Gnanaolivu R, Lilyquist J, Lee KY, Gao C, Eckloff B, Anton-Culver H, Auer P, Bernstein L, Gaudet M, Haiman C, Palmer J, Tentham-Dietz A, ... ... Polley EC, et al. Abstract 4169: Population-based breast cancer risk estimates associated with cancer predisposition gene mutations from 32,298 breast cancer patients and 31,869 matched unaffected controls from the CARRIERS study Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4169 |
0.409 |
|
| 2019 |
Hughitt VK, Gorjifard S, Michalowski AM, Simmons JK, Dale R, Polley EC, Keats JJ, Mock BA. Abstract 5113: A flexible pipeline for precision medicine biomarker detection and prediction of treatment response Cancer Research. 79: 5113-5113. DOI: 10.1158/1538-7445.Am2019-5113 |
0.414 |
|
| 2018 |
Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, ... ... Polley EC, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics. PMID 30554720 DOI: 10.1016/J.Ajhg.2018.11.002 |
0.388 |
|
| 2018 |
Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, et al. The NCI Transcriptional Pharmacodynamics Workbench: a tool to examine dynamic expression profiling of therapeutic response in the NCI-60 cell line panel. Cancer Research. PMID 30355619 DOI: 10.1158/0008-5472.Can-18-0989 |
0.335 |
|
| 2018 |
Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, Polley EC, Bowman ED, Khan MA, Robles AI, Cooks T, Ryan BM, Padgett N, Dzutsev AH, Trinchieri G, et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biology. 19: 123. PMID 30143034 DOI: 10.1186/S13059-018-1501-6 |
0.334 |
|
| 2018 |
Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, ... ... Polley EC, et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute. PMID 30099541 DOI: 10.1093/Jnci/Djy106 |
0.398 |
|
| 2018 |
Antwi SO, Fagan SE, Chaffee KG, Bamlet WR, Hu C, Polley EC, Hart SN, Shimelis H, Lilyquist J, Gnanaolivu RD, McWilliams RR, Oberg AL, Couch FJ, Petersen GM. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Journal of the National Cancer Institute. PMID 29982661 DOI: 10.1093/Jnci/Djx272 |
0.378 |
|
| 2018 |
Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Jama. 319: 2401-2409. PMID 29922827 DOI: 10.1001/Jama.2018.6228 |
0.382 |
|
| 2018 |
Hart SN, Hoskin T, Shimelis H, Moore RM, Feng B, Thomas A, Lindor NM, Polley EC, Goldgar DE, Iversen E, Monteiro ANA, Suman VJ, Couch FJ. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 29884841 DOI: 10.1038/S41436-018-0018-4 |
0.321 |
|
| 2018 |
Kasi PM, Couch F, Bamlet WR, Hu C, Hart S, Polley E, Petersen GM, McWilliams RR. Germline BRCA1/2, PALB2, and ATM mutations in 3,030 patients with pancreatic adenocarcinoma: Survival analysis of carriers and noncarriers. Journal of Clinical Oncology. 36: 280-280. DOI: 10.1200/Jco.2018.36.4_Suppl.280 |
0.352 |
|
| 2018 |
Couch F, Shimelis H, Dolinsky JS, Polley E, Horton C, Yussuf A, Hoang L, Lilyquist J, Speare V, Hu C, Hart S, LaDuca H. Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes. Journal of Clinical Oncology. 36: 1524-1524. DOI: 10.1200/Jco.2018.36.15_Suppl.1524 |
0.414 |
|
| 2018 |
Fasching P, Hu C, Hart S, Polley E, Lee K, Gnanolivu R, Lilyquist J, Hartkopf A, Taran F, Janni W, Hadji P, Tesch H, Haeberle L, Ettl J, Lux M, et al. Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-02 |
0.414 |
|
| 2018 |
Couch F, Shimelis H, LaDuca H, Hu C, Hart S, Polley E, Pesaran T, Tippin-Davis B, Goldgar D, Dolinsky J. Abstract PD1-01: Triple negative breast cancer predisposition genes Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-01 |
0.438 |
|
| 2018 |
Lilyquist J, Laduca H, Hu C, Na J, Polley E, Hart S, Pesaran T, Tippin-Davis B, Goldgar D, Dolinsky J, Couch F. Abstract P6-09-02: Associations between hereditary cancer panel predisposition genes and breast cancer histological subtypes Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-09-02 |
0.42 |
|
| 2018 |
Liu M, Cummings S, Vachon C, Kerlikowske K, Couch F, Morris E, Olson J, Polley E, Conners A, Ellis R, Patel B, Maimone S, Zhang N, Hamilton S, Clarke C, et al. Abstract OT3-02-01: Development of cell-free nucleic acid-based tests for early detection of breast cancer: The STRIVE study Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-02-01 |
0.403 |
|
| 2017 |
Lilyquist J, LaDuca H, Polley E, Davis BT, Shimelis H, Hu C, Hart SN, Dolinsky JS, Couch FJ, Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecologic Oncology. PMID 28888541 DOI: 10.1016/J.Ygyno.2017.08.030 |
0.402 |
|
| 2017 |
Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead MG, Anderson LW, Polley EC, Rubinstein L, Srivastava AK, Wilsker DF, Collins JM, Doroshow JH. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer Research. PMID 28446463 DOI: 10.1158/0008-5472.Can-17-0489 |
0.385 |
|
| 2017 |
Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Jama Oncology. PMID 28418444 DOI: 10.1001/Jamaoncol.2017.0424 |
0.413 |
|
| 2017 |
Yang SX, Polley EC, Nguyen D. Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer. Theranostics. 7: 945-951. PMID 28382166 DOI: 10.7150/Thno.19102 |
0.341 |
|
| 2017 |
Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, ... ... Polley EC, et al. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. The Journal of Molecular Diagnostics : Jmd. PMID 28188106 DOI: 10.1016/J.Jmoldx.2016.10.007 |
0.361 |
|
| 2017 |
Yang SX, Polley E. Survival profile in breast cancer molecular subtypes without systemic and locoregional treatment. Journal of Clinical Oncology. 35: 11599-11599. DOI: 10.1200/Jco.2017.35.15_Suppl.11599 |
0.345 |
|
| 2017 |
Couch F, Hu C, Lilyquist J, Shimelis H, Akinhanmi M, Na J, Polley E, Hart S, McFarland R, LaDuca H, Huether R, Goldgar D, Dolinsky J. Abstract S2-01: Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S2-01 |
0.434 |
|
| 2017 |
Couch F, Lilyquist J, Na J, Hu C, Polley E, Shimelis H, Akinhanmi M, McFarland R, LaDuca H, Goldgar D, Dolinsky J. Abstract P5-09-03: Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-09-03 |
0.428 |
|
| 2017 |
Greathouse L, White J, Bliskovsky V, Vargas A, Polley E, Bowman E, Khan M, Robles A, Ryan B, Dzutsev A, Trinchieri G, Pineda M, Bilke S, Meltzer P, Walther-Antonio M, et al. Abstract 4925: Microbiome-TP53 gene interaction in human lung cancer Cancer Research. 77: 4925-4925. DOI: 10.1158/1538-7445.Am2017-4925 |
0.353 |
|
| 2017 |
LaDuca H, Hu C, Shimelis H, Polley E, Lilyquist J, Black MH, Davis BT, Goldgar DE, Dolinsky J, Couch FJ. Abstract 4286: What have we learned from pancreatic cancer patients undergoing multigene panel testing Epidemiology. 77: 4286-4286. DOI: 10.1158/1538-7445.Am2017-4286 |
0.34 |
|
| 2017 |
Lilyquist J, LaDuca H, Polley E, Shimelis H, Hu C, Moore R, Hart SN, Couch FJ, Dolinsky J, Goldgar DE. Abstract 1287: Multigene panel testing and risk estimates in 10,233 ovarian cancer cases Epidemiology. 77: 1287-1287. DOI: 10.1158/1538-7445.Am2017-1287 |
0.33 |
|
| 2016 |
Palmisano A, Zhao Y, Li MC, Polley EC, Simon RM. OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials. Briefings in Bioinformatics. PMID 27422621 DOI: 10.1093/bib/bbw059 |
0.343 |
|
| 2016 |
Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, et al. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. Journal of the National Cancer Institute. 108. PMID 27247353 DOI: 10.1093/Jnci/Djw122 |
0.326 |
|
| 2016 |
Chang LC, Das B, Lih CJ, Si H, Camalier CE, McGregor PM, Polley E. RefCNV: Identification of Gene-Based Copy Number Variants Using Whole Exome Sequencing. Cancer Informatics. 15: 65-71. PMID 27147817 DOI: 10.4137/Cin.S36612 |
0.327 |
|
| 2016 |
Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treatment Reviews. 45: 87-96. PMID 26995633 DOI: 10.1016/J.Ctrv.2016.03.004 |
0.412 |
|
| 2016 |
Goldstein BA, Polley EC, Briggs FB, van der Laan MJ, Hubbard A. Testing the Relative Performance of Data Adaptive Prediction Algorithms: A Generalized Test of Conditional Risk Differences. The International Journal of Biostatistics. 12: 117-29. PMID 26529567 DOI: 10.1515/Ijb-2015-0014 |
0.615 |
|
| 2016 |
Chen AP, Williams M, Kummar S, Lih C, Datta V, Polley E, Zhao Y, Rubinstein L, O'Sullivan Coyne GH, Meehan RS, Moore N, Sharon E, Palmisano A, Sims D, Harrington R, et al. Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study. Journal of Clinical Oncology. 34: 2539-2539. DOI: 10.1200/Jco.2016.34.15_Suppl.2539 |
0.366 |
|
| 2015 |
Kaur G, Reinhart RA, Monks A, Evans D, Morris J, Polley E, Teicher BA. Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Letters. PMID 26683772 DOI: 10.1016/J.Canlet.2015.12.001 |
0.372 |
|
| 2015 |
Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, et al. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. The Journal of Molecular Diagnostics : Jmd. PMID 26602013 DOI: 10.1016/J.Jmoldx.2015.07.006 |
0.387 |
|
| 2015 |
Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J. Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Molecular Cancer Therapeutics. 14: 2452-62. PMID 26351324 DOI: 10.1158/1535-7163.Mct-15-0074 |
0.34 |
|
| 2015 |
Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM. GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer Informatics. 14: 45-55. PMID 25861217 DOI: 10.4137/Cin.S17282 |
0.381 |
|
| 2015 |
Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH. Application of molecular profiling in clinical trials for advanced metastatic cancers. Journal of the National Cancer Institute. 107. PMID 25663694 DOI: 10.1093/Jnci/Djv003 |
0.383 |
|
| 2015 |
Kaur G, Polley E, Morris J, Silvers T, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Monks A, Rapisarda A, Evans D, Teicher BA. Abstract 5406: Osteosarcoma cell lines response to approved and investigational anticancer agents and statins along with gene and microRNA expression Cancer Research. 75: 5406-5406. DOI: 10.1158/1538-7445.Am2015-5406 |
0.324 |
|
| 2014 |
Kummar S, Williams M, Lih C, Chen AP, Rubinstein L, Antony R, Polley E, Zhao Y, Conley BA, Simon R, Doroshow JH. NCI mpact: National Cancer Institute molecular profiling-based assignment of cancer therapy. Journal of Clinical Oncology. 32: TPS2642-TPS2642. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2642 |
0.37 |
|
| 2014 |
Polley E, Monks A, Morris J, Rapisarda A, Kaur G, Mertins S, Connelly J, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Evans D, Teicher BA. Sarcoma gene expression and response to approved and investigational agents: Focus on osteosarcoma. Journal of Clinical Oncology. 32: e22067-e22067. DOI: 10.1200/Jco.2014.32.15_Suppl.E22067 |
0.323 |
|
| 2014 |
Morris J, Kunkel M, Polley E, Holbeck S, Monks A, Evans D, Rapisarda A, Collins J, Teicher B. Abstract 5475: Interrogation of NCI-60 patterns of growth inhibition in conjunction with investigational oncology agents kinase profiling for the elucidation of mechanistic targets Cancer Research. 74: 5475-5475. DOI: 10.1158/1538-7445.Am2014-5475 |
0.334 |
|
| 2014 |
Evans DM, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Silvers T, Connelly J, Monks A, Polley E, Kaur G, Morris J, Teicher B. Abstract 5450: Screening more than 60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets Cancer Research. 74: 5450-5450. DOI: 10.1158/1538-7445.Am2014-5450 |
0.336 |
|
| 2014 |
Wrzeszczynski KO, Polley EC, Hose C, Monks A, Teicher BA. Abstract 2361: Identification and analysis of gene fusion and splice variant events in the NCI sarcoma cell line panel Cancer Research. 74: 2361-2361. DOI: 10.1158/1538-7445.Am2014-2361 |
0.374 |
|
| 2014 |
Lih C, Sims D, Harrington R, Polley E, Zhao Y, Simon R, Mehaffey M, Forbes T, Walsh W, Datta V, Conley B, Chen A, Kummar S, Doroshow J, Williams P. 233 Analytical validation and application of the MPACT assay, a next generation sequencing based targeted mutation detection assay for treatment selection European Journal of Cancer. 50: 78. DOI: 10.1016/S0959-8049(14)70359-4 |
0.301 |
|
| 2014 |
Hose C, Zhao Y, Polley E, Fang J, Fer N, Rapisarda A, Teicher B, Simon R, Doroshow J, Monks A. 171 Antagonistic interaction between gemcitabine and erlotinib is influenced by EGR1 (early growth response 1) transcription factor expression European Journal of Cancer. 50: 57. DOI: 10.1016/S0959-8049(14)70297-7 |
0.332 |
|
| 2013 |
Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Research. 73: 4372-82. PMID 23856246 DOI: 10.1158/0008-5472.Can-12-3342 |
0.394 |
|
| 2013 |
Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiology and Drug Safety. 22: 111-21. PMID 22674782 DOI: 10.1002/Pds.3297 |
0.465 |
|
| 2013 |
Simon R, Polley E. Clinical trials for precision oncology using next-generation sequencing Personalized Medicine. 10: 485-495. DOI: 10.2217/Pme.13.36 |
0.354 |
|
| 2013 |
Monks A, Rapisarda A, Wrzeszczynski KO, August EM, Polley EC, Kondapaka SB, Kaur G, Newton D, Teicher BA. Abstract 4361: Target and drug discovery for recalcitrant, rare and neglected cancers. Cancer Research. 73: 4361-4361. DOI: 10.1158/1538-7445.Am2013-4361 |
0.41 |
|
| 2013 |
Hays JL, Polley EC, David JJ, Lu J, Leone AM, Mehta S, Kohn EC. Abstract C124: Proteomic and phenotype derived model for selection of combinations of targeted therapies in ovarian cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C124 |
0.373 |
|
| 2013 |
Monks A, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Rapisarda A, Kunkel M, Morris J, Wrzeszczynski K, Polley E, Teicher B. Abstract C103: Sarcoma cell line sensitivity towards approved oncology drugs and investigational agents identifies distinct patterns of response which can be interrogated with associated gene expression. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C103 |
0.363 |
|
| 2013 |
Morris J, Kunkel M, Polley E, Holbeck S, Wrzeszczynski K, Monks A, Evans D, Rapisarda A, Collins J, Teicher BA. Abstract A102: NCI-60 response profiles of >400 investigational oncology agents: A resource enabling drug and biomarker discovery. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A102 |
0.357 |
|
| 2013 |
Lih C, Sims D, Polley E, Zhao Y, Mehaffey M, Forbes T, Harrington R, Walsh W, McGregor P, Simon R, Conley B, Kummar S, Doroshow J, Williams P. MC13-0060 Analytical validation of the MPACT assay, a targeted next generation sequencing clinical assay for cancer patient treatment selection European Journal of Cancer. 49: S11. DOI: 10.1016/S0959-8049(13)70117-5 |
0.351 |
|
| 2012 |
Abaan OD, Davis SR, Bilke S, Polley EC, Walker RL, Pineda M, Zhu YJ, Reinhold W, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS. Abstract 1879: The exomes of the NCI60 and their implications for cancer pharmacogenomics Cancer Research. 72: 1879-1879. DOI: 10.1158/1538-7445.Am2012-1879 |
0.411 |
|
| 2011 |
Namiki T, Tanemura A, Valencia JC, Coelho SG, Passeron T, Kawaguchi M, Vieira WD, Ishikawa M, Nishijima W, Izumo T, Kaneko Y, Katayama I, Yamaguchi Y, Yin L, Polley EC, et al. AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proceedings of the National Academy of Sciences of the United States of America. 108: 6597-602. PMID 21460252 DOI: 10.1073/Pnas.1007694108 |
0.337 |
|
| 2010 |
Kilpatrick R, Bradbury B, Gilbertson D, Brookhart M, Polley E, Rothman K. Using IPTW Marginal Structural Modeling to Balance Confounding by Indication Annals of Epidemiology. 20: 717. DOI: 10.1016/J.Annepidem.2010.07.075 |
0.45 |
|
| 2007 |
van der Laan MJ, Polley EC, Hubbard AE. Super learner. Statistical Applications in Genetics and Molecular Biology. 6: Article25. PMID 17910531 DOI: 10.2202/1544-6115.1309 |
0.58 |
|
| 2007 |
Sinisi SE, Polley EC, Petersen ML, Rhee SY, van der Laan MJ. Super learning: an application to the prediction of HIV-1 drug resistance. Statistical Applications in Genetics and Molecular Biology. 6: Article7. PMID 17402922 DOI: 10.2202/1544-6115.1240 |
0.662 |
|
| Show low-probability matches. |